世界中医药
世界中醫藥
세계중의약
WORLD CHINESE MEDICINE
2014年
2期
237-241
,共5页
芪苈强心胶囊%慢性心力衰竭%Meta分析
芪藶彊心膠囊%慢性心力衰竭%Meta分析
기력강심효낭%만성심력쇠갈%Meta분석
Exercise-based cardiac rehabilitation%Coronary heart disease%Chronic heart failure%Meta-analysis
目的:系统评价芪苈强心胶囊治疗慢性心力衰竭的有效性和安全性。方法:计算机检索2008年至2013年9月Cochrane图书馆临床对照试验资料库、Embase、Pubmed、中国学术期刊全文数据库、中国生物医学文献数据库、万方数据库、维普数据库,收集芪苈强心胶囊治疗慢性心力衰竭的试验,按纳入和排除标准共纳入28项研究2536例患者,使用RevMan 5.0软件进行Meta分析。结果:芪苈强心胶囊可改善慢性心力衰竭患者的预后:1)降低NTpro-BNP及BNP:治疗组NTpro-BNP低于对照组[SMD=-1.57,95%CI(-1.79,-1.34),P<0.00001],治疗组BNP低于对照组[SMD=-0.60,95%CI(-0.77,-0.43),P<0.00001];2)治疗组改善NYHA心功能分级效果好于对照组[OR=3.48.95%CI(2.66,4.55),P<0.00001];3)治疗组6分钟步行试验距离远于对照组[SMD=1.03,95%CI(0.91,1.16),P<0.00001];4)治疗组左室射血分数明显高于对照组[SMD=1.06,95%CI(0.96,1.16),P<0.00001];5)治疗组不良反应发生率低于对照组[OR=0.23.95% CI(0.11,0.47),P<0.00001]。结论:根据目前研究结果,芪苈强心胶囊对改善慢性心力衰竭患者的心功能和生活质量是安全有效的。
目的:繫統評價芪藶彊心膠囊治療慢性心力衰竭的有效性和安全性。方法:計算機檢索2008年至2013年9月Cochrane圖書館臨床對照試驗資料庫、Embase、Pubmed、中國學術期刊全文數據庫、中國生物醫學文獻數據庫、萬方數據庫、維普數據庫,收集芪藶彊心膠囊治療慢性心力衰竭的試驗,按納入和排除標準共納入28項研究2536例患者,使用RevMan 5.0軟件進行Meta分析。結果:芪藶彊心膠囊可改善慢性心力衰竭患者的預後:1)降低NTpro-BNP及BNP:治療組NTpro-BNP低于對照組[SMD=-1.57,95%CI(-1.79,-1.34),P<0.00001],治療組BNP低于對照組[SMD=-0.60,95%CI(-0.77,-0.43),P<0.00001];2)治療組改善NYHA心功能分級效果好于對照組[OR=3.48.95%CI(2.66,4.55),P<0.00001];3)治療組6分鐘步行試驗距離遠于對照組[SMD=1.03,95%CI(0.91,1.16),P<0.00001];4)治療組左室射血分數明顯高于對照組[SMD=1.06,95%CI(0.96,1.16),P<0.00001];5)治療組不良反應髮生率低于對照組[OR=0.23.95% CI(0.11,0.47),P<0.00001]。結論:根據目前研究結果,芪藶彊心膠囊對改善慢性心力衰竭患者的心功能和生活質量是安全有效的。
목적:계통평개기력강심효낭치료만성심력쇠갈적유효성화안전성。방법:계산궤검색2008년지2013년9월Cochrane도서관림상대조시험자료고、Embase、Pubmed、중국학술기간전문수거고、중국생물의학문헌수거고、만방수거고、유보수거고,수집기력강심효낭치료만성심력쇠갈적시험,안납입화배제표준공납입28항연구2536례환자,사용RevMan 5.0연건진행Meta분석。결과:기력강심효낭가개선만성심력쇠갈환자적예후:1)강저NTpro-BNP급BNP:치료조NTpro-BNP저우대조조[SMD=-1.57,95%CI(-1.79,-1.34),P<0.00001],치료조BNP저우대조조[SMD=-0.60,95%CI(-0.77,-0.43),P<0.00001];2)치료조개선NYHA심공능분급효과호우대조조[OR=3.48.95%CI(2.66,4.55),P<0.00001];3)치료조6분종보행시험거리원우대조조[SMD=1.03,95%CI(0.91,1.16),P<0.00001];4)치료조좌실사혈분수명현고우대조조[SMD=1.06,95%CI(0.96,1.16),P<0.00001];5)치료조불량반응발생솔저우대조조[OR=0.23.95% CI(0.11,0.47),P<0.00001]。결론:근거목전연구결과,기력강심효낭대개선만성심력쇠갈환자적심공능화생활질량시안전유효적。
Objective:To systematically review the effects of Qili Qiangxin capsule treating chronic heart failure .Methods:Clinical trials on Qili Qiangxin capsules treating chronic heart failure ( CHF) published during 2008 and September 2013 were searched from the follow-ing electronic databases including Cochrane Library , Embase, PubMed, CNKI, CBM, Wanfang, VIP.Altogether 28 studies including 2536 patients were included in the review , and the data were analyzed by using Review Manager 5.0.Results:Qili Qiangxin capsule can improve the prognosis of chronic heart failure .Meta-analysis results showed that , 1) Reducing the levels of N-terminal Pro of Pro-brain natriuretic peptide (NT-pro BNP) and brain natriuretic peptide(BNP):the level of NT-pro BNP of the treatment group was lower than that of the control group [SMD=-1.57,95%CI(-1.79,-1.34),P<0.000 01],the level of BNP in treatment was lower than that of the control group [SMD=-0.60,95%CI(-0.77,-0.43),P<0.000 01];2) Treatment group better improved cardiac function NYHA [OR=3.48.95%CI(2.66,4.55),P<0.000 01];3) The distance of 6-minute walking test was longer in treatment group [SMD=1.03,95%CI(0.91,1.16),P<0.000 01];4) Treatment group better improved the left ventricular ejection fraction [SMD=1.06,95%CI(0.96,1.16),P<0.000 01];5) The incidence of adverse reactions was lower in treatment group [OR=0.23.95%CI (0.11,0.47),P<0.000 01].Conclusion:Qili Qiangxin Capsule can obviously improve the cardiac function and the quality of life of patients with chronic heart failure , and it is safe and effective .